YesidAlvarado ValeroMD

PubMed

• 190 citations
  10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 t...
  Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi
  The Lancet. Haematology. 2020-09-05
• 114 citations
  Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
  Curtis Lachowiez, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Gautam Borthakur
  Blood Advances. 2020-04-14
• 81 citations
  Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
  Abhishek Maiti, Caitlin R. Rausch, Jorge E. Cortes, Naveen Pemmaraju, Naval Daver
  Haematologica. 2020-06-04

Abstracts/Posters

• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all